CNS Pharmaceuticals shares surge 16.02% after-hours as three abstracts accepted for SNO 2025 meeting highlight berubicin and TPI 287 data.

CNS Pharmaceuticals Inc. surged 16.02% in after-hours trading following the announcement that three abstracts detailing its clinical trial results for drug candidates Berubicin and TPI 287 were accepted for poster presentation at the Society of Neuro-Oncology (SNO) 30th Annual Meeting. The presentations include preliminary data on Berubicin’s activity against pediatric diffuse midline glioma, a planned Phase 2 trial of TPI 287 combined with bevacizumab for glioblastoma, and primary results comparing Berubicin to lomustine in glioblastoma treatment. These updates highlight potential advancements in CNS’s pipeline for central nervous system cancers, likely driving investor optimism about the company’s therapeutic progress and future clinical opportunities.